Back دينوسوماب Arabic Denosumab German Δενοσουμάμπη Greek Denosumab Spanish Denosumab French דנוסומאב HE Denosumab Italian デノスマブ Japanese 데노수맙 Korean Denosumab Latin

Denosumab

Denosumab
Denosumab injection
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetRANK ligand
Clinical data
Trade namesProlia, Xgeva, others
Other namesAMG-162
Biosimilarsdenosumab-bbdz, Jubbonti,[1][2] Wyost[3]
AHFS/Drugs.comMonograph
MedlinePlusa610023
License data
Pregnancy
category
  • AU: D
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityN/A
MetabolismProteolysis
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6404H9912N1724O2004S50
Molar mass144722.80 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Denosumab, sold under the brand names Prolia and Xgeva among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.[8][9]

Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.[10]

Denosumab is an inhibitor of RANKL (receptor activator of nuclear factor kappa-Β ligand),[8] which works by decreasing the development of osteoclasts, which are cells that break down bone. It was developed by the biotechnology company Amgen.[11]

  1. ^ a b "Regulatory Decision Summary for Jubbonti". Drug and Health Products Portal. 16 February 2024. Archived from the original on 1 April 2024. Retrieved 1 April 2024.
  2. ^ a b Cite error: The named reference Jubbonti EPAR was invoked but never defined (see the help page).
  3. ^ a b "Regulatory Decision Summary for Wyost". Drug and Health Products Portal. 1 March 2024. Archived from the original on 1 April 2024. Retrieved 1 April 2024.
  4. ^ "Prolia- denosumab injection". DailyMed. 24 January 2024. Archived from the original on 7 June 2023. Retrieved 6 March 2024.
  5. ^ "Xgeva- denosumab injection". DailyMed. 9 June 2020. Archived from the original on 13 April 2023. Retrieved 6 March 2024.
  6. ^ Cite error: The named reference Prolia EPAR was invoked but never defined (see the help page).
  7. ^ Cite error: The named reference Xgeva EPAR was invoked but never defined (see the help page).
  8. ^ a b Pageau SC (2009). "Denosumab". mAbs. 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634. Archived from the original on 8 March 2012. Retrieved 27 March 2011.
  9. ^ McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. (February 2006). "Denosumab in postmenopausal women with low bone mineral density". The New England Journal of Medicine. 354 (8): 821–31. doi:10.1056/NEJMoa044459. PMID 16495394.
  10. ^ Cite error: The named reference EMEA was invoked but never defined (see the help page).
  11. ^ "Prolia (denosumab)". Products. Amgen. Archived from the original on 29 September 2015. Retrieved 6 May 2012.

Rich TVX News Network Site

Rich TVX News Network Info

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search